secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncternal Therapeutics, Inc. (—)
CIK:        0001260990
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056882
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncternal Q1 net loss $8.4M; ONCT-534 cohort fully enrolled; cash runway into Q1 2025
--------------------------------------------------------------------------------

- Net loss $8.4M ($2.83 per share); grant revenue $0.6M; total operating expenses $9.3M including $1.4M stock-based compensation.
- Cash, cash equivalents & short-term investments $27.0M as of March 31, 2024; no debt; projected runway into Q1 2025.
- Phase 1/2 ONCT-534 for advanced prostate cancer: fourth cohort (300 mg/day) fully enrolled; initial data expected late Q2 2024.
- Phase 1/2 ONCT-808 (ROR1 CAR T) for aggressive B-cell lymphoma open and enrolling; clinical update expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/0000950170-24-056882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/onct-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer